Related Experiment Videos
The cost-effective way forward for the management of the patient with heart failure
1School of Medicine, Louisiana State University Medical Center, New Orleans, USA.
Insights
Heart failure treatments, including angiotensin-converting enzyme inhibitors and nurse practitioners, improve patient outcomes and reduce healthcare costs. These therapies effectively manage disease progression and enhance quality of life.
Area of Science:
- Cardiology
- Health Economics
Background:
- Heart failure presents a significant healthcare challenge, demanding cost-effective management strategies.
- Assessing treatment cost-effectiveness involves evaluating disease progression, patient quality of life, and overall disease management expenses.
Purpose of the Study:
- To review the cost-effectiveness of heart failure therapies.
- To highlight the impact of pharmacological and non-pharmacological interventions on healthcare costs and patient benefits.
Main Methods:
- Literature review of landmark heart failure trials (e.g., CONSENSUS, SOLVD, SAVE).
- Analysis of direct costs (hospitalization) and indirect costs (lost productivity).
- Evaluation of non-pharmacological interventions like nurse practitioner support.
Main Results:
- Angiotensin-converting enzyme inhibitors demonstrate effectiveness in improving disease progression, quality of life, and cost-effectiveness.
- Non-pharmacological strategies, particularly nurse practitioner involvement, positively impact both costs and patient benefits.
Conclusions:
- Angiotensin-converting enzyme inhibitors are a cost-effective treatment for heart failure.
- Integrating nurse practitioners into heart failure management enhances patient outcomes and optimizes resource utilization.
Abstract:
Heart failure is a huge healthcare issue not only for clinicians but for healthcare managers also, with increasing pressure to demonstrate the cost-effectiveness of therapies especially for common chronic conditions. The cost-effectiveness of heart failure treatments relate to their effects on the progression of the disease, the associated quality of life for the patient, and the actual cost of the disease management. Direct costs are usually associated with hospitalization. Indirect costs, such as the loss of production through absence from work, are more difficult to determine. Studies such as CONSENSUS, SOLVD, SAVE and the Munich Heart Failure trial have all shown that angiotensin-converting enzyme inhibitors offer effective therapy in all these aspects. Non-pharmacological strategies that have also been shown to favorably influence both the costs and benefit include the addition of a nurse practitioner to assist in patient management.